Revvity (NYSE:RVTY) Price Target Raised to $105.00 at JPMorgan Chase & Co.

Revvity (NYSE:RVTY) had its target price hoisted by JPMorgan Chase & Co. from $100.00 to $105.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

RVTY has been the topic of a number of other research reports. Guggenheim assumed coverage on Revvity in a research note on Wednesday, October 15th. They issued a “neutral” rating on the stock. Barclays boosted their target price on shares of Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Tuesday. Bank of America downgraded shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price target for the company. in a report on Monday, December 15th. Robert W. Baird set a $129.00 price objective on Revvity in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Revvity in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $113.67.

Revvity Stock Performance

Shares of NYSE RVTY opened at $100.85 on Tuesday. The company has a market cap of $11.43 billion, a P/E ratio of 48.49, a P/E/G ratio of 3.22 and a beta of 1.07. Revvity has a 52-week low of $81.36 and a 52-week high of $124.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.68. The firm’s fifty day moving average is $103.99 and its two-hundred day moving average is $95.57.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, February 2nd. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business had revenue of $772.06 million during the quarter, compared to the consensus estimate of $759.81 million. During the same quarter in the prior year, the firm earned $1.42 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. As a group, analysts anticipate that Revvity will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s payout ratio is 14.07%.

Revvity declared that its Board of Directors has approved a share repurchase program on Monday, October 27th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to buy up to 8.7% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Revvity

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ethic Inc. raised its position in Revvity by 15.6% in the 4th quarter. Ethic Inc. now owns 10,511 shares of the company’s stock valued at $1,017,000 after purchasing an additional 1,420 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Revvity by 11.4% during the 4th quarter. Sequoia Financial Advisors LLC now owns 36,359 shares of the company’s stock worth $3,518,000 after purchasing an additional 3,728 shares during the period. Gateway Investment Advisers LLC increased its holdings in Revvity by 28.5% in the fourth quarter. Gateway Investment Advisers LLC now owns 4,596 shares of the company’s stock valued at $445,000 after buying an additional 1,019 shares in the last quarter. Truist Financial Corp raised its holdings in Revvity by 0.8% during the fourth quarter. Truist Financial Corp now owns 45,120 shares of the company’s stock worth $4,365,000 after purchasing an additional 356 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in shares of Revvity in the 4th quarter worth about $216,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported stronger-than-expected Q4 results: adjusted EPS $1.70 (above estimates) and revenue $772.1M (+5.9% YoY). Management raised FY‑2026 guidance (EPS $5.35–5.45; revenue ~ $3.0B), which sits slightly above consensus. These beats and the raised guidance are the primary fundamental positives supporting the stock. Reuters: Revvity forecasts 2026 profit, revenue above estimates
• Positive Sentiment: Multiple analysts lifted price targets after the results — TD Cowen to $124 (buy), Wells Fargo to $110 (equal weight), and JPMorgan to $105 (neutral) — signaling continued analyst support and upside in some research houses. The Fly: TD Cowen raise Benzinga: analyst notes
• Neutral Sentiment: Full earnings call transcript, slide deck and presentation are available for deeper review — useful for assessing segment trends (diagnostics strength vs. academic research weakness) but neutral until investors digest details. Seeking Alpha: Q4 transcript
• Neutral Sentiment: Analyst/market commentary highlights Revvity as a momentum name and reviews key metrics vs. estimates — useful framing for traders but not new primary drivers. Zacks: momentum piece
• Negative Sentiment: Despite the positive news, shares fell today — trading volume was above average — suggesting profit-taking, short‑term rotation, or valuation concerns (RVTY’s trailing P/E is elevated). The market may be pricing a higher bar for sustained upside even after the beat and upgrades.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.